FDA Approves DALFAMPRIDINE — Micro Labs Limited

FDA has granted tentative approval to Micro Labs Limited for the generic version of dalfampridine tablets, introducing a cost-effective alternative to SQYBB Inc.'s Ampyra amid expected competition that may pressure market pricing. This approval, following the loss of the drug’s exclusivity, could drive down acquisition costs for channel partners while benefiting patients reliant on this orally administered therapy for walking difficulties.